grant
Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer
Organization SLOAN-KETTERING INST CAN RESEARCHLocation NEW YORK, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY20263-D3-Dimensional3DAdjuvant ChemotherapyAdjuvant Drug TherapyAnti-ERB-2Anti-HER2/c-erbB2 Monoclonal AntibodyAnti-c-ERB-2Anti-c-erbB2 Monoclonal AntibodyAnti-erbB-2Anti-erbB2 Monoclonal AntibodyAnti-p185-HER2BiologicalBiological MarkersBiologyBiopsyBiopsy SampleBiopsy SpecimenBloodBlood Reticuloendothelial SystemBlood SampleBlood specimenBody TissuesCancer ModelCancerModelCaringCell ComponentsCell StructureCellular StructuresCheckpoint inhibitorChemotherapy and RadiationChemotherapy and/or radiationClinicalClinical TrialsCollectionColon CancerColon CarcinomaColorectal CancerColostomyColostomy ProcedureCombined Modality TherapyCorrelative StudyDataDependenceDimerizationDiseaseDisorderDistalDrugsERBB2ERBB2 geneEnrollmentFrequenciesGene TranscriptionGenetic TranscriptionGoalsHER -2HER-2HER2HER2 GenesHER2 Monoclonal AntibodyHER2/neuHerceptinIRBIRBsImmune checkpoint inhibitorIn complete remissionIncidenceInduction TherapyInstitutional Review BoardsIntestinalIntestinesInvestigatorsMMR deficiencyMR ImagingMR TomographyMRIMRI ScansMRIsMagnetic Resonance ImagingMagnetic Resonance Imaging ScanMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMismatch Repair DeficiencyMoAb HER2ModalityModelingMolecularMorbidityMultimodal TherapyMultimodal TreatmentNEOADJNEU OncogeneNEU proteinNMR ImagingNMR TomographyNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNuclear Magnetic Resonance ImagingOncogene ErbB2Operative ProceduresOperative Surgical ProceduresOrganOrganoidsPETPET ScanPET imagingPETSCANPETTPathologicPatient SelectionPatientsPharmaceutical PreparationsPhasePositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPre-Clinical ModelPreclinical ModelsPrimary NeoplasmPrimary TumorProgression-Free SurvivalsProtein DimerizationQOLQuality of lifeRNA ExpressionRad.-PETRadiationRadiographyRectal CancerRectal CarcinomaRecurrenceRecurrentRegimenResearchResearch PersonnelResearch ResourcesResearchersResistanceResourcesRoentgenographySamplingSex DisordersSexual DysfunctionSurgicalSurgical InterventionsSurgical ProcedureTKR1TestingTissue SampleTissuesToxic effectToxicitiesTranscriptionTrastuzumabZeugmatographyarmbio-markersbiologicbiologic markerbiomarkerbiomarker drivenbowelc-erb-2 Monoclonal Antibodyc-erbB-2c-erbB-2 Genesc-erbB-2 Proto-Oncogenescancer in the coloncheck point blockadecheckpoint blockadechemo-/radio-therapychemo-radiotherapychemo/radiation therapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapychemotherapychemotherapy and radiotherapycirculating tumor DNA assaycirculating tumor DNA assessmentcirculating tumor DNA evaluationcirculating tumor DNA monitoringcirculating tumor DNA profilingcirculating tumor DNA screeningcirculating tumor DNA testingcolon cancer patientscolorectal cancer patientscombination therapycombined modality treatmentcombined treatmentcomplete responsecopy number alterationctDNA assayctDNA assessmentctDNA evaluationctDNA monitoringctDNA profilingctDNA screeningctDNA testingdesigndesigningdetermine efficacydrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationenrollerbB-2 Genesevaluate efficacyexamine efficacyexperiencefluoropyrimidineherstatinimmune check point blockadeimmune check point inhibitorimmune checkpoint blockadeimprovedinduction therapiesmetastatic colo-rectalmetastatic colo-rectal cancermetastatic colo-rectal carcinomametastatic colon cancermetastatic colorectalmetastatic colorectal cancermetastatic colorectal carcinomamulti-modal therapymulti-modal treatmentneu Genespharmacodynamic biomarkerpharmacodynamic markerphase 2 studyphase II studypositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographypredict responsivenesspredicting responseprogramsradiation or chemotherapyradio-chemo-therapyradio-chemotherapyradiochemotherapyradiological imagingresistance mechanismresistantresistant mechanismresponseresponse biomarkerresponse markersrhuMAb HER2standard carestandard of carestandard treatmentsuccesssurgerytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapy optimizationthree dimensionaltreatment optimizationtumortumor DNAtumor cell DNAtumor-specific DNAurinary
Description preview
PROJECT SUMMARY/ABSTRACT
Current standard tri-modality therapy (chemotherapy, radiation, and surgery) for locally advanced rectal cancer
is associated with high morbidity and only cures disease in about 75% of patients. We hypothesize that a
biomarker-driven approach that gives matched targeted therapy to patients early in the treatment of locally…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click